[
  {
    "ts": null,
    "headline": "Why Investors Should Consider Certara Again",
    "summary": "Certara posted strong Q1 and Q2 results, with revenue growth and non-GAAP EPS exceeding expectations. Click here to find out why CERT stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=43b0f57e1f443cda3f5327cb934f9930c537db510f4c1eed2e3c6576a1b1963b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760550940,
      "headline": "Why Investors Should Consider Certara Again",
      "id": 137098915,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1140489368/image_1140489368.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Certara posted strong Q1 and Q2 results, with revenue growth and non-GAAP EPS exceeding expectations. Click here to find out why CERT stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=43b0f57e1f443cda3f5327cb934f9930c537db510f4c1eed2e3c6576a1b1963b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers",
    "summary": "New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinomaTARRYTOWN, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology (ESMO) 2025 Meeting, taking place from October 17-21 in",
    "url": "https://finnhub.io/api/news?id=bb3a60ba6e6377f9cd5d461d44e3351c1fe6443caad16b6cd36424e3d4f60dc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760526000,
      "headline": "Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers",
      "id": 137094508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinomaTARRYTOWN, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology (ESMO) 2025 Meeting, taking place from October 17-21 in",
      "url": "https://finnhub.io/api/news?id=bb3a60ba6e6377f9cd5d461d44e3351c1fe6443caad16b6cd36424e3d4f60dc7"
    }
  }
]